Caliber Imaging & Diagnostics' VivaScan Procedure Featured

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Caliber Imaging & Diagnostics' VivaScan Procedure Featured on Los Angeles NBC-TV Affiliate

BOSTON and ROCHESTER, N.Y., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., was featured in a news segment on NBC4 affiliate in Los Angeles (KNBC-TV) and an accompanying online article on July 10.

The health report by Dr. Bruce Hensel, titled "High-Tech System Detects Skin Cancer Without Biopsy," focuses on the Company's VivaScan™ procedure using a VivaScope ® , which can aide in the detection of skin cancer and eliminate unnecessary biopsies. The segment interviews a patient who undergoes a VivaScan administered by Dr. Babar Rao at NIDIskin (Non-Invasive Diagnostic Imaging of the Skin) Consulting, located at 8383 Wilshire Boulevard in Beverly Hills, California.

To view the segment in its entirety and read the article, please visit the following link:

http://www.nbclosangeles.com/news/local/Optic...10041.html

The video at the link above is provided for informational purposes only. Caliber Imaging & Diagnostics is not responsible for the content of the linked video.

About Caliber Imaging & Diagnostics

Caliber Imaging & Diagnostics' proprietary, cutting-edge VivaScope® system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and pending patents worldwide, VivaScope has the potential to significantly improve outcomes and reduce costs. The VivaScan™ procedure, which utilizes the VivaScope for dermatological examination, allows physicians to detect cancerous lesions that appear benign, and reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the academic, medical and therapeutic research markets. For more information about Caliber I.D. and its products, please visit www.caliberid.com .

VivaScope® is a registered trademark of Caliber Imaging & Diagnostics.

VivaScan™ is a trademark of Caliber Imaging and Diagnostics.

Safe Harbor

This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including the statements regarding the potential for future product revenue growth and financial performance. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.

Caliber Imaging & Diagnostics Richard Christopher Chief Financial Officer (617) 348-9821 or Dian Griesel Int'l. Susan Forman or Laura Radocaj (212) 825-3210

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Habitat for Humanity AZ's Unique Gala: An Overview

Updated Category News Views 56

Mark Your Calendars: A Night to Celebrate Listen up, Central Arizona, because I'm giving you the lowdown on Habitat for Humanity Central Arizona's big night out. "Blueprints & Blue Jeans" - it's the gala that's ditching the formalities for some good old-fashioned community fun, but with a seriously important mission at its heart. Mark your calendars for Friday, March 5,...

Continue Reading
Radiation Oncology Text Earns Doody's 2026 Nod

Updated Category News Views 122

Recognition in Radiation Oncology In the rapidly advancing arena of radiation oncology, staying current is no small feat. But here's a feather in the cap of one publication doing just that: Fundamentals of Radiation Oncology: Physical, Biological, and Clinical Aspects, 4th Edition. This resource has made quite the splash by snagging a spot on the 2026 Doody's Core Titles...

Continue Reading
Blue Owl Tech Faces Lawsuit Post-44% Share Dive

Updated Category News Views 59

The air's thick with tension for investors of Blue Owl Technology Finance Corp. (NYSE:OTF) as they wake up to the news of a securities class action lawsuit that's no small fry. You don’t have to look too far to see why the folks holding the bag might be steamed. We’re talking about a 44% drop in stock price since the merger with Blue Owl Technology Finance Corp....

Continue Reading
TELUS Targets Debt Reduction Amid Telecom Transformation

Updated Category News Views 99

Adjusting Strategy Amid Financial Challenges The market's a tough beast, and TELUS seems to be wrestling with it, showing both grit and foresight in its latest quarterly update. Third quarter 2026 has TELUS down on revenues with a notable net loss but don't count them out yet. Their Transformation Strategy is a gamble worth watching. Where the Numbers Stand Here's the...

Continue Reading
Havertys Dividend: A Steady Payout Tradition Continues

Updated Category News Views 87

Another Year, Another Dividend for Havertys Man, talk about a company with a rock-solid habit. Havertys Furniture Companies (NYSE: HVT) just announced its latest cash dividend, cementing a tradition that's been rolling since 1935. They're dropping $0.33 per share on the common stock and $0.31 on the Class A common stock. It's set to hit investors' pockets by December 9,...

Continue Reading
Koppers Faces Investigation: Investors Cautious Amid Probe

Updated Category News Views 128

Deep Dive: Koppers' Financial Turmoil When a company throws a financial party, you don't expect the hangover to come in the form of an investigation notice. That’s what’s brewing over at Koppers Holdings Inc., leading many seasoned investors to take a hard, scrutinizing look at the books. The latest buzz? An inquiry into whether the company gave its investors the full...

Continue Reading
Tenax Therapeutics Faces Legal Heat After Stock Plunge

Updated Category News Views 92

Investors' Nerves Tested as Tenax Takes a Nosedive Holy smokes! When a biotech company like Tenax Therapeutics, Inc. (NASDAQ: TENX) detonates like a forgotten fireworks stash, investors have every right to get itchy. Tenax’s shocking announcement that their Phase 3 LEVEL trial for TNX-103 flopped has sparked more than just shareholder anxiety. It’s ignited a...

Continue Reading
Koppers Navigates Q3: Margins Squeeze Amid Growth

Updated Category News Views 110

Investing in Koppers: A Mixed Bag in Q3 Well, it appears Koppers (NYSE: KOP) is doing a bit of a dance this quarter—some smooth steps, but a few stumbles in the rhythm when it comes to margins. The hardwood numbers tell an interesting tale, so let's break it down. Sales Edge Up, But Margins Suffer Koppers clocked in net sales of $499.1 million for the third quarter of...

Continue Reading
Encompass Health Faces Uncertain Future with Sea Pines

Updated Category News Views 119

Unexpected Downpour Closes Sea Pines They say when it rains, it pours. That's not just true in life, but as it happens, it's quite literal in Melbourne, Florida. A deluge of biblical proportions forced an immediate lockdown of the Sea Pines Rehabilitation Hospital. Flooded to the gills, this once stalwart institution finds its doors shuttered indefinitely. It's a...

Continue Reading
Clean Energy: How COP31 Can Change the Future

Updated Category News Views 141

Global Warming: A Battle Heating Up Fast It's like trying to run uphill while carrying the baggage of outdated promises. We’ve got business bigwigs rallying at COP31, demanding the world to get serious about clean energy. If they don’t, we're looking at warming rocketing up to 2.6°C come year 2100. Who's listening though? The Call for Clean Electrification This mob,...

Continue Reading

Top 5 Most Recently Viewed Articles

Growing Demand in Pharmaceutical Excipients Market by 2031

Updated Category News Views 182

Let’s cut to the chase—the pharmaceutical excipients market is heating up. It's not just a smattering of growth here and there; we’re talking about a projected value that’s set to smash through USD 17.13 billion by 2031. That’s a juicy compound annual growth rate (CAGR) of 6.8% from 2024 to 2031 according to SkyQuest Technology. Why the Surge? What's fueling...

Continue Reading
Natural Retreats Enhances Guest Experience with Track Software

Updated Category News Views 354

Natural Retreats Elevates Guest Experience with New Tech Natural Retreats, a leader in the luxury vacation rental market, is making waves with its recent partnership with Track Hospitality Software. This collaboration marks a pivotal shift in how the company operates, ensuring that customer service reaches new heights. By adopting Track's cloud-based property management...

Continue Reading
Lower Factory Input Prices Signal Inflation Relief

Updated Category Economy Views 323

U.S. Manufacturing Sector Contracts for Third Consecutive Month June's U.S. manufacturing sector contracted for the third month running. From 48.7 in May, the Institute for Supply Management (ISM) recorded that its manufacturing PMI dropped to 48.5 in June. A PMI reading less than fifty suggests contraction. Ten percent or so of the U.S. economy is manufacturing....

Continue Reading
Investors Brace for Talen Energy's Earning Report This Week

Updated Category News Views 159

Talen Energy: Prepping for the Earnings Showdown Pencil this one in: February 26, 2026. That’s the big day when Talen Energy (NASDAQ:TLN) rolls out its quarterly earnings report. Investors are chomping at the bit, as EPS is projected to hit a solid $3.68. Get your game faces on folks, because this one could shake up sentiment across the board. The Whisperer’s Corner:...

Continue Reading
Legal Insights: Sage Therapeutics Under Investigation for Alleged Misconduct

Updated Category News Views 119

Understanding the Investigation Surrounding Sage Therapeutics The legal world is buzzing with developments concerning Sage Therapeutics, Inc. (NASDAQ: SAGE), a prominent name in the pharmaceutical industry. Recently, Faruqi & Faruqi, LLP—a respected national securities law firm—has ramped up efforts to investigate potential claims on behalf of investors interested in...

Continue Reading